GlassScriptPhysician profile
Ross A Parks
NPI 1447251277
$5,841.93
in general payments reported to CMS, 2019-2025
28 companies · $1,466 in 2025
The $1,466 reported for 2025 was more than what 84% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $814 · 2020: $184 · 2021: $475 · 2022: $177 · 2023: $1,121 · 2024: $1,604 · 2025: $1,466.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,191.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,191.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,296.18 | 2019-2025 | Clareon, Rocklatan, Centurion |
| Abbvie INC. | $911.41 | 2022-2025 | |
| Aerie Pharmaceuticals, INC. | $430.89 | 2019-2021 | |
| Glaukos Corporation | $383.61 | 2021-2024 | Ce-Marked Kxla System |
| Bausch & Lomb Americas INC. | $311.02 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Oyster Point Pharma, INC. | $220.39 | 2022-2025 | Tyrvaya, Ryzumvi |
| Sun Pharmaceutical Industries INC. | $219.53 | 2019-2025 | |
| Amgen INC. | $205.36 | 2025 | Tepezza |
| Allergan, INC. | $183.71 | 2019-2020 | |
| Apellis Pharmaceuticals, INC. | $182.90 | 2024-2025 | Syfovre |
| Dompe US, INC. | $178.49 | 2024-2025 | Oxervate |
| Harrow Eye, LLC | $176.80 | 2024-2025 | Vevye |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $154.18 | 2019-2021 | |
| Tarsus Pharmaceuticals, INC. | $145.87 | 2025 | Xdemvy |
| Johnson & Johnson Surgical Vision, INC. | $116.51 | 2019 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rxsight INC | $112.19 | 2022-2023 | Rxsight Contact Lens, Rxsight Light Delivery Device (Ldd), Rxsight Injector Cartridge |
| Kala Pharmaceuticals, INC. | $109.74 | 2019 | |
| Mallinckrodt Hospital Products INC. | $106.49 | 2023-2025 | Acthar |
| Sight Sciences, INC. | $90.25 | 2020 | |
| Rayner Intraocular Lenses Limited | $77.82 | 2023-2025 | Rayone Spheric, Rayone Emv, Rayone Aspheric |
| Regeneron Healthcare Solutions, INC. | $51.01 | 2025 | Eylea Hd, Eylea |
| Astellas Pharma US INC | $47.25 | 2025 | Izervay |
| Novartis Pharmaceuticals Corporation | $44.04 | 2019 | |
| Genentech USA, INC. | $24.65 | 2025 | Vabysmo |
| Horizon Therapeutics Plc | $22.61 | 2023 | Tepezza |
| Akorn, INC. | $14.91 | 2020 | |
| Eyevance Pharmaceuticals LLC | $12.59 | 2019 | |
| Omeros Corporation | $11.53 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ross Parks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.